Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17129527 | PRESERVATION OF PHAGE CONCENTRATION IN CLINICAL SAMPLES | December 2020 | December 2024 | Abandon | 48 | 2 | 1 | No | No |
| 17247661 | EXTRACELLULAR VESICLES DERIVED FROM OSTEOBLAST LINEAGE CELLS FOR THERAPEUTIC AND DIAGNOSTIC USE | December 2020 | February 2025 | Abandon | 50 | 3 | 1 | Yes | No |
| 17118555 | COMPOSITION AND METHOD FOR INDUCTION OF PLURIPOTENT STEM CELL | December 2020 | December 2024 | Abandon | 48 | 2 | 1 | No | No |
| 17116332 | GENOME-EDITED INDUCED PLURIPOTENT STEM CELLS, AND CELLS DERIVED THEREFROM, AND USES THEREOF | December 2020 | August 2024 | Allow | 44 | 1 | 1 | No | No |
| 16973108 | ENGINEERED HEMATOPOIETIC STEM CELLS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA | December 2020 | November 2024 | Abandon | 48 | 1 | 1 | No | No |
| 17104528 | PLATELETS LOADED WITH mRNA | November 2020 | June 2023 | Abandon | 30 | 1 | 0 | No | No |
| 17058163 | COMBINATION THERAPY WITH CHIMERIC ANTIGEN RECEPTOR (CAR) THERAPIES | November 2020 | August 2024 | Abandon | 45 | 0 | 1 | No | No |
| 17053668 | CELL SCAFFOLD MATERIAL | November 2020 | August 2024 | Abandon | 45 | 0 | 1 | No | No |
| 17043836 | Composition For Inducing Dedifferentiation From Somatic Cells To Induced Pluripotent Stem Cells And Method of Inducing Dedifferentiation Using Same | September 2020 | March 2024 | Allow | 42 | 1 | 1 | No | No |
| 17036476 | COMPOSITION THAT CONTAINS POLYLYSINE ANALOG AND PROMOTES CELL GROWTH | September 2020 | February 2024 | Abandon | 40 | 0 | 1 | No | No |
| 16981421 | CRYOPRESERVING PROCESSES | September 2020 | January 2024 | Allow | 40 | 1 | 0 | No | No |
| 16981077 | REAGENTS AND METHODS WITH WNT AGONISTS AND BIOACTIVE LIPIDS FOR GENERATING AND EXPANDING CARDIOMYOCYTES | September 2020 | June 2025 | Allow | 57 | 3 | 1 | Yes | No |
| 16978573 | HUMAN PAPILLOMAVIRUS VACCINES AND USES OF THE SAME | September 2020 | April 2025 | Allow | 55 | 2 | 1 | No | No |
| 16977106 | COMPOSITIONS FOR USE IN THE TREATMENT OF MUSCULOSKELETAL CONDITIONS AND METHODS FOR PRODUCING THE SAME LEVERAGING THE SYNERGISTIC ACTIVITY OF TWO DIFFERENT TYPES OF MESENCHYMAL STROMAL/STEM CELLS | September 2020 | November 2024 | Abandon | 50 | 3 | 1 | Yes | No |
| 16971634 | MORPHOGENIC COMPOUND-RELEASING MICROSPHERES AND USE IN BIOINK | August 2020 | May 2025 | Abandon | 57 | 3 | 1 | Yes | No |
| 16994336 | METHODS FOR NUCLEAR REPROGRAMMING OF CELLS | August 2020 | March 2024 | Allow | 43 | 2 | 1 | Yes | No |
| 16958013 | ARTIFICIAL TISSUE PERFUSION DEVICE AND METHOD OF DRUG ASSESSMENT USING ARTIFICIAL TISSUE | July 2020 | April 2024 | Abandon | 46 | 0 | 1 | No | No |
| 16962880 | METHOD FOR PRODUCING EXOSOMES AND EXOSOMES OBTAINED THEREBY | July 2020 | June 2023 | Allow | 35 | 2 | 0 | Yes | No |
| 16957010 | MESENCHYMAL STROMAL CELLS AND METHODS FOR OBTAINING MESENCHYMAL STROMAL CELLS FROM UMBILICAL CORD | June 2020 | November 2024 | Abandon | 53 | 2 | 1 | No | No |
| 16956500 | METHOD FOR ISOLATING HUMAN DERMAL FIBROBLASTS | June 2020 | March 2024 | Abandon | 45 | 2 | 1 | No | No |
| 16652803 | APPLICATION OF PLURIPOTENT STEM CELLS HAVING MODIFIED DIFFERENTIAL POTENTIAL TO PRODUCING ANIMALS | June 2020 | September 2023 | Abandon | 42 | 1 | 1 | Yes | No |
| 16756067 | CARTILAGE TISSUE PRODUCING METHOD AND CARTILAGE TISSUE | April 2020 | January 2024 | Abandon | 45 | 2 | 0 | No | No |
| 16820316 | METHOD FOR THE TREATMENT OF CANCERS BY MEANS OF GENETIC NEUROENGINEERING | March 2020 | October 2023 | Abandon | 43 | 1 | 1 | No | No |
| 16644808 | NOVEL CELL LINE AND USES THEREOF | March 2020 | July 2023 | Allow | 41 | 1 | 1 | Yes | No |
| 16641137 | BIOENGINEERED IN VITRO 3D MODEL OF HUMAN ATHEROSCLEROTIC PLAQUE | February 2020 | November 2023 | Allow | 45 | 2 | 1 | Yes | No |
| 16638693 | COMPOSITIONS AND METHODS FOR ENHANCING MATURATION STATES OF HEALTHY AND DISEASED CARDIOMYOCYTES | February 2020 | May 2024 | Abandon | 51 | 2 | 1 | No | No |
| 16638483 | METHODS OF MATURATION OF HUMAN SPERMATOGONIUM | February 2020 | July 2024 | Abandon | 53 | 4 | 1 | No | No |
| 16776503 | COMPOSITIONS AND METHODS FOR REGULATING PROTEINS AND NUCLEIC ACIDS ACTIVITIES | January 2020 | December 2023 | Allow | 46 | 2 | 1 | Yes | No |
| 16629402 | THE METHOD OF AUTOLOGOUS PRIMARY HAIR FOLLICLES PREPARATION IN 3D CULTURE | January 2020 | October 2024 | Allow | 58 | 5 | 0 | No | No |
| 16607836 | GENERATING HUMAN CELLS CAPABLE OF PRODUCING INSULIN IN RESPONSE TO GLUCOSE OR GLP-1 | October 2019 | July 2024 | Abandon | 57 | 1 | 1 | No | No |
| 15536725 | TRANSGENIC RPE CELLS OVEREXPRESSING OTX2 FOR THE TREATMENT OF RETINAL DEGENERATION | June 2017 | August 2023 | Allow | 60 | 7 | 1 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner STAVROU, CONSTANTINA E works in Art Unit 1632 and has examined 31 patent applications in our dataset. With an allowance rate of 38.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 46 months.
Examiner STAVROU, CONSTANTINA E's allowance rate of 38.7% places them in the 7% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by STAVROU, CONSTANTINA E receive 1.90 office actions before reaching final disposition. This places the examiner in the 42% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by STAVROU, CONSTANTINA E is 46 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +38.6% benefit to allowance rate for applications examined by STAVROU, CONSTANTINA E. This interview benefit is in the 85% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 20.0% of applications are subsequently allowed. This success rate is in the 24% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 33.3% of cases where such amendments are filed. This entry rate is in the 50% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants file petitions regarding this examiner's actions, 50.0% are granted (fully or in part). This grant rate is in the 44% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.